1 Combined PD-L1 and TIM-3 blockade improves the expansion of fit

2 human CD8+ antigen-specific T cells for adoptive immunotherapy

- 4 Shirin Lak¹, Valérie Janelle¹, Anissa Djedid², Gabrielle Boudreau¹, Ann Brasey^{1,3}, Véronique Lisi², Cédric
- 5 Carli¹, Lambert Busque^{1,3,4,5}, Vincent-Philippe Lavallée^{2,6,7}, Jean-Sébastien Delisle^{1,4,5}
- 6
- ¹ Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
- 8 ² Centre de recherche du CHU Sainte-Justine, Montréal, Qc, Canada
- 9 ³ Biomarker Unit, Centre C3i, Montréal, Qc, Canada
- 10 ⁴ Department of Medicine, Université de Montréal, Montréal, Qc, Canada
- ⁵ Hematology-Oncology and Cell therapy Division, Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
- 12 ⁶ Department of Pediatrics, Université de Montréal, Montréal, Qc, Canada
- 13 ⁷ Hematology-Oncology Division, CHU Sainte-Justine CHU Sainte-Justine
- 14
- 15 Correspondence to:
- 16 Jean-Sébastien Delisle MD, FRCPC, PhD
- 17 Centre de recherche de l'Hôpital Maisonneuve-Rosemont
- 18 5415, Boul de L'Assomption
- 19 Montréal, Qc H1T 2M4
- 20 Canada
- 21 js.delisle@umontreal.ca
- 22
- 23
- 24 Word count
- 25 Abstract: 343
- 26 Main text: 5081 27

28 **Declarations**

29 Ethics approval and consent to participate. Informed consent was obtained from all cell donors as 30 detailed in the Method section.

- 31 Consent for publication. All authors have reviewed the final version and agreed with the submission. The 32 corresponding author agrees to pay the publication charges.
- Availability of data and material. As detailed in the Methods section, the genomic data have been deposited for public access and agree to share protocols. All materials used are commercially available.
- 35 **Competing interest.** The authors have no relevant conflict of interest to disclose.
- Funding. This work was funded by the Leukemia/Lymphoma Society of Canada (grants #622735 and #430053) to JSD.

Authors' contribution. SL and JSD conceived the study. SL, VJ, AB, CC performed experiments. SL, VJ, AB, AD, GB, VL analyzed data. LB, VPL, JSD oversaw data analysis. SL, VJ and JSD wrote the manuscript.

40 All authors reviewed the manuscript.

Acknowledgments. The authors are grateful to the volunteer blood donors and Héma-Québec for the leukocytes reduction chamber procurement and handling. We also acknowledge the valuable contribution of Martine Dupuis (flow cytometry and sorting) and the Genome Québec staff for the single-cell RNAsequencing. SL and VJ are respectively former Cole Foundation and Fonds de recherche du Québec-Santé (FRQS) studentship awardees, JSD and VPL hold FRQS clinician-scientist career awards and JSD is a member of the ThéCell network and of the Canadian Donation and Transplant Research Program (CDTRP).

49 List of Abbreviations

50	ACT	Adoptive Cell Therapy
51	APC	Antigen Presenting Cell
52	CCR7	C-C chemokine receptor type 7
53	CD	Cluster of differentiation
54	CDR	Complementarity Determining Region
55	CTLA-4	Cytotoxic T-lymphocyte-associated protein 4
56	CTLs	Cytotoxic T-lymphocytes
57	CTV	Cell Trace Violet
58	CTY	Cell Trace Yellow
59	DC	Dendritic Cell
60	DMSO	Dimethylsulfoxide
61	EBV	Epstein-Barr virus
62	ELISPOT	Enzyme-linked mmune absorbent spot
63	FBS	Fetal Bovine Serum
64	FOXP3	Forkhead Box P3
65	Gal-9	Galectin-9
66	GM-CSF	Granulocyte-Macrophage Colony-Stimulating Factor
67	GrzB	GranzymeB
68	HLA	Human Leukocyte Antigen
69	HMGB1	High Mobility Group Protein B1
70	IFN	Interferon
71	lg	Immunoglobulin
72	IL	Interleukin
73	KLRG1	Killer cell Lectin-like Receptor G1
74	LAG-3	Lymphocyte-Activation Gene 3
75	LRSC	Leuko Reduction System Chamber
76	mAB	Monoclonal Antibody
77	MHC	Major Histocompatibility Complex
78	NGS	Next-generation Sequencing
79	PBMC	Peripheral Blood Mononuclear Cell
80	PBS	Phosphate-buffered saline
81	PD-1	Programmed Cell Death-1
82	PD-L1	Programmed Death Ligand-1
83	PGE2	Prostaglandin E2
84	PHA	T-cell mitogen phytohemagglutinin
85	PMA	Phorbol 12-myristate 13-acetate

86	PS	Phosphatidyl Serin
87	RT	Room Temperature
88	SC-RNA	Singel Cell RNA
89	ТАА	Tumor-Associated Antigen
90	TAP	Transporter associated with Antigen Processing
91	Tcm	Central Memory T cell
92	TCR	T-cell Receptor
93	Teff	Effector T cell
94	Tem	Effector Memory T cell
95	TGF-β	Transforming Growth Factor-β
96	TIM-3	T-cell Immunoglobulin and Mucin-domain Containing-3
97	ТМВ	3,3',5,5'-Tetramethylbenzidine
98	TNF	Tumor Necrosis Factor
99	TSA	Tumor-Specific Antigen
100	Tscm	Stem-cell Like memory T cells
101	WT1	Wilms' tumor suppressor gene1
102		

103 Abstract

Background. The stimulation and expansion of antigen-specific T cells *ex vivo* enables the targeting of a multitude of cancer antigens. However, clinical scale T-cell expansion from rare precursors requires repeated stimulations *ex vivo* leading to T-cell terminal effector differentiation and exhaustion that adversely impact therapeutic potential. We leveraged immune checkpoint blockade relevant to antigen-specific CD8+ human T cells to improve the expansion and function of T cells targeting clinically relevant antigens.

Methods. A clinically-compliant protocol relying on peptide-pulsed monocyte-derived dendritic cells and cytokines was used to expand antigen-specific CD8⁺ targeting the oncogenic Epstein-Barr virus (EBV) and the tumor associated antigen (TAA) Wilms Tumor 1 (WT1) protein. The effects of antibody-mediated blockade of immune checkpoints applied to the cultures (T-cell expansion, phenotypes and function) were assessed at various time points. Genomic studies including single cell RNA (scRNA) sequencing and Tcell receptor sequencing was performed on EBV-specific T cells to inform about the impact of immune

115 checkpoint blockade on the clonal distribution and gene expression of the expanded T cells.

116 Results. Several immune checkpoints were expressed early by ex vivo expanded antigen-specific CD8⁺ T 117 cells, including PD-1 and TIM-3 with co-expression matching evidence of T-cell dysfunction as the cultures 118 progressed. The introduction of anti-PD-L1 (expressed by the dendritic cells) and anti-TIM-3 antibodies in 119 combination (but not individually) to the culture led to markedly improved antigen-specific T-cell expansion 120 based on cell counts, fluorescent multimer staining and functional tests. This was not associated with 121 evidence of T-cell dysfunction when compared to T cells expanded without immune checkpoint blockade. 122 Genomic studies largely confirmed these results, showing that double blockade does not impart particular 123 transcriptional programs or patterns on TCR repertoires. However, our data indicate that combined 124 blockade may nonetheless alter gene expression in a minority of clonotypes and have donor-specific 125 impacts.

126 Conclusions. The manufacturing of antigen-specific CD8⁺ T cells can be improved in terms of yield and 127 functionality using blockade of TIM-3 and the PD-L1/PD-1 axis in combination. Overcoming the deleterious 128 effects of multiple antigenic stimulations through PD-L1/TIM-3 blockade is a readily applicable approach for 129 several adoptive-immunotherapy strategies.

131 Background

132 The vast majority of potentially actionable cancer antigens are major histocompatibility (MHC)-bound 133 peptides. These include tumor-specific antigens (TSA) resulting from mutated proteins or aberrantly 134 expressed regions of the genome, tumor associated antigens (TAA) that come from abnormally expressed 135 self-proteins and finally, non-self peptides best described in the setting of virus-associated cancers or 136 allogeneic stem cell transplantation¹². While it has been possible to isolate TSA or TAA-specific T-cell 137 receptors (TCR) and manufacture TCR-transgenic T cells for adoptive immunotherapy, this approach faces 138 numerous technical hurdles and is currently available only for a minority of relevant cancer antigens³. 139 Several effective adoptive immunotherapy strategies rely on the ex vivo expansion of native antigen-specific 140 T cells, enabling the targeting of a vast array of antigens. However, the expansion of large numbers of 141 antigen-specific T cells requires repeated antigen exposure (through co-culture with antigen-presenting 142 cells – APC) and stimulatory cytokines, potentially leading to T-cell dysfunction (terminal effector differentiation and exhaustion) and poor performance following adoptive transfer⁴⁻⁶. 143

144

145 Alternatively, the endogenous cancer-reactive T-cell repertoire can be mobilized through the systemic 146 administration of antibodies that prevent signaling from inhibitory co-signaling receptors present on the surface of exhausted T cells^{7 8}. Such "immune-checkpoint" blockade, targeting most commonly Cytotoxic 147 148 T-lymphocyte-associated protein 4 (CTLA-4) and Programmed death-1 (PD-1) on T cells (or its 149 corresponding primary ligand, Programmed death-ligand 1 - PD-L1), is now the cornerstone of therapeutic regimes against several types of neoplasia including advanced melanoma and lung cancer⁹. As 150 151 dysfunctional cancer-reactive T cells often express multiple negative co-signaling molecules, a strategy has 152 been to use combined approaches with the caveat that increased response may come with more immune-153 related toxicities¹⁰. Ex vivo expanded T cells express inhibitory receptors, and PD-L1/PD-L2 silenced 154 antigen-presenting dendritic cells have been shown to improve the expansion and function of antigen-155 specific T cells ex vivo¹¹, thus providing a solid rationale to leverage immune checkpoint blockade to 156 improve T-cell manufacturing for adoptive immunotherapy.

158 We show herein that the ex vivo expansion of CD8+ T cells specific for a viral antigen and a TAA is 159 enhanced by using combined PD-L1 and T-cell immunoglobulin and mucin-containing protein-3 (TIM-3) 160 blockade, while single blockade or either receptor fails to improve T-cell expansion. The generated antigen-161 specific T cells did not show phenotypic and functional evidence of exhaustion or terminal effector 162 differentiation. This was corroborated with single-cell RNA (sc-RNA) and VD(J) sequencing, which revealed 163 that dual immune checkpoint blockade can impact T-cell gene expression in a donor and clonotype-164 dependent fashion. Taken together, our results show that dual PD-L1/TIM-3 blockade during ex vivo 165 expansion can yield large quantities of fit human antigen-specific T cells for adoptive immunotherapy.

167 Methods

168 **Donors and cellular procurement**

169 Peripheral blood mononuclear cells (PBMCs) from HLA-A0201 expressing volunteer donors were isolated 170 using Ficoll-Hypaque gradient (STEMCELL Technologies) from fresh whole blood (collected by 171 venipuncture) or leukoreduction system chambers provided by Héma-Québec (LRSCs) as previously 172 described^{12 13}. All donors provided written informed consent, and all the experiments were approved by the 173 Héma-Québec and Hôpital Maisonneuve-Rosemont Research Ethics Committees. Recovered PBMCs 174 were either used immediately for experiments or resuspended in freezing media (90% fetal bovine serum and 10% dimethyl sulfoxide (DMSO)), transferred to Mr. Frosty containers (NALGENE[™] Cryo 1^{oC} freezing 175 container), and stored in vapor-phase liquid nitrogen for future use. 176

177 Dendritic Cells (DCs) differentiation and antigen pulsing

178 Monocyte isolation and DC differentiation have been generated as previously described⁴. Briefly, 179 monocytes were obtained using the adherence method whereby PBMCs were plated in adherent plastic 180 plates (Sarstedt) in media (X-Vivo 15 medium (LONZA) supplemented with 5% human serum, 2 mM L-181 glutamine and 1mM Sodium Pyruvate (Gibco), 1000 U/ml (100 ng/ml) IL-4 and 800 U/ml (50ng/ml) GM-182 CSF (Both from STEMCELL technologies)) and incubated in a CO₂, 37°C incubator for 7 days. On day 4, 183 media was replaced with fresh media supplemented with IL-4 and GM-CSF. On day 7, DCs were matured 184 with maturation media containing 1000 U/ml (100 ng/ml) IL-4, 800 U/ml (50ng/ml) GM-CSF (Both from 185 STEMCELL technologies), 10 ng/ml TNF-α (STEMCELL technologies), 1 μg/ml PGE2 (SIGMA), 10 ng/ml 186 IL-1β (Feldan), 100 ng/ml IL-6 (Miltenyi Biotec) and loaded with desired peptide (1 µg/mL LMP2₄₂₆₋₄₃₄ 187 (CLGGLLTMV) or 1 µg/mL WT137-45 (VLDFAPPGA), both from JPT Peptides. Lastly, DC media was 188 supplemented with IFN-y 1000U/ml (Feldan) for the last 24 hours of culture.

189 Ex Vivo expansion of antigen-specific T cells

Antigen-specific T cells were stimulated using a clinically compliant protocol as previously described (⁴ and www.clinicaltrials.gov NCT03091933) from 15x10⁶ PBMCs and expanded through multiple weekly stimulations using irradiated (40 Gy) autologous, peptide-loaded monocyte-derived DCs at a 1:10

193 (DC:PBMC) in a G-Rex6® Well Plate vessel (Wilson Wolf Manufacturing, New Brighton, MN). Our complete 194 T-lymphocyte culture (CTL) media (Advanced RPMI 1640, 10% human serum, 1X L-glutamine(Gibco)) was 195 supplemented with the following cytokines; week 1: IL-21 (30 ng/mL) and IL-12 (10 ng/ mL) (Both from 196 Feldan), week 2: IL-21, IL-2 (100 IU/mL), IL-7 (10 ng/mL) and IL-15 (5 ng/mL) (STEMCELL Technologies), 197 subsequent weeks: IL-2, IL-7 and IL-15. Medium, including cytokines, was refreshed every 3 to 4 days, and 198 specific T cell cultures were restimulated once every week with peptide-loaded monocyte-derived DCs 199 (moDCs). Cell concentration was adjusted to 1:10 ratio each week. When indicated, cultures were 200 supplemented with 20 µg/ml of anti-PD-L1 blocking mAb (BioXcell, 29E.2A3) or/and 10 µg/ml of anti-TIM3 201 blocking mAb (Biolegend, F38-2E2) with all media changes. Respective isotype antibodies, mouse IgG1 202 (BioXcell, MOPC-21) and InVivoMAb mouse IgG2b (BioXcell, MPC-11), were used at the same 203 concentration where indicated. All cell cultures were performed in monitored incubators (37°C in 5% CO₂ 204 and 5% air humidity). Cell viability and cell counts were assessed by the countess automated cell counter 205 (Invitrogen) using trypan blue (Invitrogen) at a 1:1 ratio with the cellular suspension in cell counting chamber 206 slides (Invitrogen-C10283).

207 Flow cytometry

208 The phenotype of mature DCs was assessed by cell surface expression of the following markers (antibody 209 clone in parenthesis) CD80 (L307.4), CD86 (2331, FUN1), HLA-ABC (W6-32), CD11c (3.9), CD19 (HIB19) 210 (all from BD Biosciences)), HLA-DR (LN3), and CD83 (HB15e) (both from Invitrogen). To detect antigenspecific CD8⁺ T cells, up to 10⁶ cells were suspended in phosphate-buffered saline (PBS) plus 2% fetal 211 212 bovine serum (FBS) and stained with allophycocyanin (APC) labeled tetramers, MHC-Dextramers A*0201 213 (Immudex,), for 10 minutes in the dark at 4°C. For additional cell surface markers and phenotyping, cells 214 were stained with following antibodies: CD3 (SKY7), CD3 (UCHT1), CD8 (SK1), CD45RO (UCHL1), 215 CD45RA (5H9), CCR7 (150503), LAG3 (T47.530), and CD4 (RPA-T4) all from BD Biosciences; CD62L 216 (DREG-56), TIM3 (F38-2E2), PD-1 (EH12.2H7), KLRG1 (2F1/KLRG1), CD57 (HCD57), and PD-L1 (29E.2A3) from Biolegend and CD8 (RPA-T8) and CD244 (eBioDM244) from Invitrogen. Staining was 217 performed at room temperature (RT) in the dark for 30 minutes. According to the manufacturer's instructions 218 219 for intracellular detection of cytokines, cells were permeabilized, fixed and stained using the Foxp3 /

Transcription Factor Staining Buffer Set (eBioscience). Before the fixation step, up to 10⁶ cells were 220 221 stimulated to produce cytokines with the indicated peptide (0.5 µg/ml) (test condition) or PMA (50 ng/mL)-222 ionomycin (500 ng/mL) (Sigma-Aldrich) (positive control) and an irrelevant peptide (HLA-A0201 restricted 223 but not used as a stimulator in the culture-negative control) for 4 h at 37°C. Cells are suspended in CTL 224 media plus brefeldin A (Biolegend) to block the secretion of cytokines during the stimulation period. Cells 225 were then harvested and stained for cell-surface markers, including CD3, CD4, and CD8 in 4 °C for 20 226 minutes. Next, fixed and permeabilized cells were stained with intracellular cytokine detection antibodies; 227 IFN-y (4S.B3), IL-2 (MQ1-17H12), and TNF- α (Mab11) all purchased from BD Biosciences) and Ki67 (ki-228 67) from Biolegend at RT for 20 minutes. Cell acquisition was performed on a Fortessa or LSR II flow 229 cytometer (BD Biosciences), and data were analyzed with Flowlogic Software (inivai).

230 IFN-γ Enzyme-linked immune-spot (ELISpot)

231 ELISPOT assays were performed using Human IFN- ELISpotPLUS kit (MABTECH), following the 232 manufacturer's instruction. Briefly, pre-coated wells were washed 5 times with sterile PBS (200ul/well), then 233 incubated with CTL media (100 ul/well) for 30 minutes in a 37 °C incubator with 5% CO₂. Cultured cells 234 were added (5×10⁴) to wells in duplicates and then stimulated with anti-CD3 mAb (positive control), 235 irrelevant peptide (specificity control), and test peptide. After an 18-hour incubation the plates were washed 236 with PBS (200ul/well) 5 times and incubated with detection antibody (7-B6-1-biotin, 1ug/ml, 100 ul/well) for 237 2 hrs at RT. Next, plates were washed with PBS (200ul/well) 5 times and incubated with streptavidin-HRP (100 ul/well) for 1 hr at room temperature. Lastly, plates were rewashed as above, and TMB substrate 238 239 solution (100 ul/well) was added in darkness. Color development was stopped by washing extensively in 240 deionized water after distinct spots emerged. Plates were dried, and the dots were counted using ELISpot 241 reader (vSpot Reader Spectrum, AID).

242 Flow Cytometry-based Cytotoxicity assay

Flow cytometry-based cytotoxicity assay was performed using either Cell Trace Violet (CTV) or Cell Trace Yellow (CTY) (Invitrogen Life Technologies) labeled LMP2₄₂₆₋₄₃₄ pulsed as target cells as described before¹⁴. Briefly, target cells were prepared by stimulating autologous PBMCs with the T-cell mitogen phytohemagglutinin (PHA) (3 × 10⁶ PBMCs/mL were incubated in T-cell media with 20 µg/mL PHA) for 3

days at 37 °C and 5% CO₂. Peptide pulsed (or not pulsed) target cells were co-cultured with LMP2-specific T cells at various ratios for 4 hours in CTL plus 10% horse serum. Unpulsed target cells alone were used as control. After incubation, cells were harvested, stained with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit, Life Technologies) according to manufacturers' instructions and viable target, cells were quantified by flow cytometry using Flow Count Beads (Beckman Coulter). Cytotoxicity was calculated by comparing the percentage of viable target cells in test conditions relative to control (100 - (Target cell alive/ Target cell alone) × 100).

254 Single-cell RNA sequencing and High-throughput TCR sequencing

255 At indicated time points, T cells were sorted based on MHC-Dextramer and CD8 staining using FACS Aria 256 III (DB Biosciences). Post sorted purity of the sorted population was 94%. A fraction of the sorted antigen-257 specific T cells was subjected to both VDJ and transcriptome sc-RNA sequencing at the Genome Quebec facilities. Briefly, cells were counted and viability assessed using a hemocytometer and Trypan Blue. The 258 259 targeted cell recovery was set at 6000 cells and libraries were prepared using the kits Chromium Next GEM 260 Single Cell 5' Kit v2 and Chromium Single Cell Human TCR Amplification Kit (10x Genomics inc.), as per 261 the manufacturer's recommendations. Libraries were quantified using the Kapa Illumina GA with Revised 262 Primers-SYBR Fast Universal kit (Kapa Biosystems). Average size fragment was determined using a 263 LabChip GX (PerkinElmer) instrument. The 10X Single cells 5' libraries were sequenced on Illumina HiSeq 264 4000 PE28x98 while the 10X Single Cells VDJ (Human T) libraries were sequenced on Illumina HiSeg 4000 265 PE150. The Illumina control software was HCS HD 3.4.0.38, the real-time analysis program was RTA v. 266 2.7.7. bcl2fastq2 v2.20 was then used to demultiplex samples and generate fastg files. Reads were aligned 267 to GRCh38 genome assembly, gene expression matrices generated, and clonotype identification 268 performed using CellRanger v3.0.2. The resulting gene expression matrices were normalised by total UMI 269 counts per cell multiplied by the median UMI count per cell and natural-log transformed using Scanpy v1.4¹⁵. 270 PhenoGraph¹⁶ clustering was applied with k=20 and clusters with a median mitochondrial fraction greater 271 than 0.2 were filtered out. Clonotypes were defined by nucleotide sequences of alpha and beta chains. In 272 order to remove potential doublets, we restricted our analysis to cells in which exactly one alpha and one 273 beta chain were identified and retained only the most abundant clonotype for each alpha and beta chain.

The number of retained cells per sample is provided in Table S1. After filtering, individual count matrices were combined and normalized and log transformed together for downstream analyses.

276

For expression analysis, only abundant clonotypes in each donor were retained. Abundant clonotypes are defined as those identified in at least 10 cells in each condition and at a frequency over all cells of a donor greater than 0.01. Pathway expression is defined as the log2 of the sum of the normalized gene expression for every gene in the pathway. Genes associated with each pathway are listed in Table S2.

281

Significance of the changes in pathway expression between the control and double blockade conditions was assessed using a Mann-Whithney U test. The p-values returned for each pathway comparison were contrasted with those obtained when comparing the expression in the DDB and CTRL conditions to those in 1000 random gene sets with the same number of genes with identical expression distribution as the pathway of interest. For each random gene set, we computed the p-value of the comparison using the Mann-Whithney U test. We report the percentile ranking of the p-value in the true pathway compared to the p-values obtained from the random gene sets.

289

290 Bulk TCR repertoire profiling was performed from sorted multimer positive and negative CD8⁺ T-cell RNA 291 preserved in Trizol reagent (Invitrogen) using Next-Generation Sequencing (NGS) targeting the 292 hypervariable complementarity-determining region 3 (CDR3) of the T cell receptor beta chain (TCR β). 293 TRIzoITM extracted RNA in combination with the PureLink RNA mini and microcolumn system (Thermo 294 Fisher), quantified by UV spectrophotometry (Tecan), and QC was completed on Bioanalyzer chip (Agilent). 295 TCRb amplicon libraries were prepared from 25 ng total RNA with the Oncomine™ TCR Beta-SR Assay 296 for RNA (ThermoFisher Scientific). The TCRb libraries obtained were quantified on the ViiA 7 Real-Time 297 PCR System with the Ion Library Tagman Quantitation kit (Thermo Fisher). NGS was completed on the Ion 298 S5 semiconductor platform using an Ion 540 chip, prepared with the Ion Chef System (all from Thermo 299 Fisher). TCR^β repertoire analysis was completed using the Ion Reporter Software (Thermo Fisher) and 300 Immunarch package¹⁷ analyses using R software. The data can be found in the Gene Expression Omnibus 301 (GSE182537 and GSE181682).

302 Statistical Analysis

- 303 Statistical significance was analyzed were with the R software, version 4.0.4. Multiple group comparisons
- 304 were performed using one-way ANOVA and Turkey post hoc test or the Kruskal-Wallis test with the Holm
- 305 procedure to correct for multiple testing (if ANOVA requirements were not met). Paired Wilcoxon-Mann-
- 306 Whitney tests were performed for two-group comparisons. p values of 0.05 or less were considered
- 307 significant.

309 Results

310 Multiple stimulations are detrimental to antigen-specific T-cell expansion ex vivo

311 Antigen-specific T cells were stimulated using moDCs loaded with the peptide LMP2426-434 (CLGGLLTMV), 312 which is an HLA-A0201 restricted antigen from the oncogenic Epstein-Barr virus (EBV). Weekly ex vivo 313 stimulations were performed in cytokine supplemented media, and antigen-specific expansion was 314 assessed before each stimulation. While overall T-cell expansion progressed following each of four 315 stimulations (albeit at limited pace after day 14 and two stimulations), the percentage and absolute number 316 of antigen-specific CD8 T cells, as identified by fluorescent HLA-0201/ LMP2426-434 multimer, stagnated 317 despite additional stimulations (Figure 1A-C). Further, this halted growth was matched with a gradual 318 change in phenotype. The predominance of central memory (Tcm) differentiation profile at day 14 evolved 319 towards an effector memory (Tem) and effector (Teff) differentiation phenotype on days 21 and 28 (Figure 320 1D). These results were anticipated as serial T-cell stimulations have been associated with the development 321 of effector T cells that gradually lose their capacity to expand and persist after adoptive transfer⁶. The 322 expression of the inhibitory receptors related to T-cell exhaustion (PD-1, TIM-3, and to a lesser extent LAG3 323 and 2B4) was substantial on a significant fraction of antigen-specific T cells at day 14, with little modulation 324 over time in culture (Figure 1E). However, the fraction of cells showing dual expression of PD-1 and TIM-3 325 increased with repeated stimulation (Figure 1F) in line with the development of CD8+ T-cell exhaustion¹⁸⁻ 326 ²⁰. Phenotyping of the moDCs revealed prevalent expression of corresponding PD-1 and TIM-3 ligands, 327 (respectively PD-L1 and CEACAM-1/Galectin 9) (Figure 1G). These results confirm and extend previous 328 data, suggesting that the early and persistent expression of PD-1 and TIM-3 by CD8⁺ T cells, along with 329 the expression of their ligands by stimulating DCs, may represent a significant hurdle for the expansion of 330 antigen-specific T cells for immunotherapy^{18 19}.

331

Combination of PD-L1/PD-1 axis and TIM-3 blockade significantly increases antigen-specific CD8⁺ T-cell expansion

In order to assess if immune checkpoint blockade during *ex vivo* expansion may improve antigen-specific T-cell yield, anti-PD-L1, anti-TIM-3, or both were added to the culture media at the beginning of culture and with all media changes. Cell counts at day 14, and even more strikingly at day 21, revealed that the double

337 blockade condition significantly increased T-cell expansion relative to control (no checkpoint blockade) and 338 the single blockade groups (Figure 2A). This translated into a marked increase in LMP2426-434-specific T-339 cell yield in the dual blockade condition despite no gain (and in fact a decline at day 14) in the percentage 340 of multimer positive CD8⁺ T cells (Figure 2B-C). In contrast, the single blockade of PD-L1 or TIM-3 offered 341 no advantage at any time point. The phenotypic assessment of LMP2426-434-specific T cells revealed no 342 statistically significant difference in the percentages of Tcm, Tem, and Teff and no difference in PD-1 or 343 TIM-3 expression (Figure 2D-E). However, the percentage of T cells expressing the inhibitory receptors 344 LAG3 and 2B4 was lower in the combined relative to the control condition. Hence, dual PD-L1 and TIM-3 345 blockade increased T-cell growth without conferring phenotypic changes associated with increased T-cell 346 dysfunction.

347

It is known that TIM-3 has a dual function. TIM-3 is transiently upregulated at intermediate levels on 348 activated T cells and confers activation signals²¹. However, in settings of chronic stimulation in the presence 349 350 of its ligands, TIM-3 inhibits T-cell activation and behaves as a bona fide immune checkpoint. We, therefore, 351 slightly modified our protocol to introduce TIM-3 blockade at day 7, a week after the first stimulation 352 (hereafter designated as delayed double blockade-DDB), with the expectation that it would further improve 353 antigen-specific T-cell yield. Compared to the dual blockade started on day 0, DDB slightly increased total 354 T-cell expansion at day 21 and more convincingly following an additional antigenic stimulation (day 28) 355 (Figure 3A). Moreover, the DDB approach increased the percentage of LMP2₄₂₆₋₄₃₄-specific T cells at all 356 time points relative to the control condition (no blocking antibodies used), including at day 14 which was 357 not the case when PD-L1 and TIM-3 blockade were both applied at day 0 (Figure 3B). Absolute antigen-358 specific counts were also increased in the DDB relative to the control condition (significant on days 21 and 359 28) (Figure 3C). Finally, DDB did not impact T-cell differentiation or exhaustion marker expression (Figure 360 3D-E). Independent cultures using isotype control antibodies confirmed the specific effects of anti-PD-L1 361 and anti-TIM-3 antibodies on the antigen-specific T-cell expansion (Supplementary Figure 1). We conclude 362 that combined blockade of the PD-L1/PD-1 axis and TIM-3 can be incorporated in ex vivo cultures to 363 increase antigen-specific CD8⁺ T-cell yield for adoptive immunotherapy without altering T-cell phenotypes.

365 Double immune checkpoint blockade generates functional antigen-specific T cells

366 Dual PD-L1 and TIM-3 blockade increases antigen-specific CD8+ T-cell expansion in culture without 367 altering T-cell phenotypes suggesting comparable functionality. Intracellular cytokine secretion 368 measurements and ELISpot assays at day 28 confirmed that a higher proportion of T cells were reactive 369 upon LMP2426-434 peptide re-exposure in the DDB condition relative to control (no checkpoint inhibition) 370 (Figure 4A-B). This was also generally the case when DDB was compared to double immune checkpoint 371 blockade administered at day 0 (statistically significant in ELISPOT data at day 28). We thus pursued our 372 functional assessments comparing DDB with the control condition. As further indication of increased 373 functionality, a greater fraction of antigen-specific T cells expanded in the DDB condition relative to control 374 expressed the proliferation marker Ki-67 and upon peptide re-exposure, more DDB exposed T cells 375 displayed evidence of cytotoxic potential (surface CD107a and intracellular granzyme B expression) (Figure 376 4C-D). This was corroborated with cytotoxicity assays showing that T cells from the DDB condition were 377 highly effective, especially at low effector: target ratios (Figure 4E-F). Importantly, in all our assays, 378 combined PD-L1 and TIM-3 blockade did not lead to increased non-specific (off-target or spontaneous) 379 cytokine release or cytotoxicity. Thus, dual immune checkpoint inhibition expands T-cell products with 380 specific and augmented antigen reactivity.

381

382 PD-L1/TIM-3 blockade imparts no consistent gene expression signatures to expanded antigen 383 specific CD8⁺ T cells

384 To gain more insight into the biological impacts of double immune checkpoint blockade on antigen-reactive 385 T cells, we submitted sorted day 28 multimer-positive T cells from three donors to paired transcriptome and 386 TCR alpha-beta single-cell RNA sequencing (scRNA-Seq). Gene expression was compared across donor, 387 condition (no checkpoint blockade vs. DDB) and clonotypes. Global gene expression patterns across the 388 three donors revealed strong donor-specific clustering (Figure 5A). The impact of DDB on gene expression 389 for each donor antigen-specific T cells, was assessed using published human T-cell gene sets²². This 390 enabled a detailed assessment of T-cell activation, proliferation, terminal differentiation, exhaustion and 391 metabolism-associated gene expression as these processes are likely to be impacted by DDB. Overall, 392 when every T cells from each condition were compared, no consistent change of gene expression signature

393 could be identified across all donors (Figure 5B). We next evaluated whether clonotype-specific signatures 394 could be identified. The sequencing of the VD(J) regions revealed that the LMP2426-434 specific T cells were 395 highly oligoclonal in all donors and conditions (1-4 clones representing more than 80% of all cells - Figure 396 5C and Supplementary Table 3). Most dominant clonotypes were shared between experimental conditions 397 (albeit at different frequencies for Donor 2) and a few clonotypes were shared between donors 398 (Supplementary Table 3). We next analyzed the expression of several pathways in the abundant clonotypes 399 (defined as those identified in at least 10 cells and representing at least 1% of the repertoire in both the 400 DDB and control conditions from the same donor). Similar to comparisons involving all clonotypes, no 401 consistent pattern was found across donors when comparing the DDB versus control condition on a per 402 clonotype basis (Figure 5D). Interestingly, our data unveiled divergent gene expression patterns for one 403 clonotype (Clonotype 3) which was shared by Donor 1 and 2. Relative to its counterpart in the control 404 condition, Donor 1 Clonotype 3 in the DDB condition expressed higher levels of genes related to T-cell 405 exhaustion/differentiation and had a lowered expression of genes associated with T-cell proliferation. The 406 same clonotype in the DDB condition from Donor 2 had, on the contrary, an increased expression of the 407 genes associated with T-cell activation without any transcriptional changes related to T-cell dysfunction (T-408 cell exhaustion, terminal differentiation, low proliferation). This suggests that donor rather than clonotype 409 related features may determine T-cell outcomes following DDB.

410

411 To assess whether clonotype-specific transcriptional signatures may impact their expansion and clonal 412 hierarchy within the cultures, we used bulk mRNA collected from sorted multimer negative and positive 413 CD8+ T cells at day 21 and 28 from the same donors. RNA of suitable quality was obtained for 23 out of a 414 potential of 24 samples (the multimer-positive fraction of the control condition from Donor 3 had to be 415 excluded) and subjected to complementary determining region 3 (CDR3) region sequencing of the T-cell 416 receptor-beta chain (TCRβ). Day 28 multimer-positive T-cell CDR3 sequencing matched very well paired 417 VDJ sequencing of single cells (Supplementary Figure 2), confirmed the oligoclonality of the multimerpositive T cells at both day 21 and 28 and revealed that TCR repertoire diversity in the multimer-negative 418 419 T cells was not affected by DDB (Figure 6A). Further, the multimer positive and negative fractions had 420 limited overlap (Supplementary Figure 3), suggesting that sorting effectively separated most CD8+ antigen-

421 specific cells from the rest of the T cells in culture. Clonotype hierarchy among multimer-positive T cells at 422 day 21 and day 28 showed no consistent pattern of evolution in DDB relative to the control condition (Figure 423 6B-C). However, the proportion of certain clonotypes in these fractions (both DDB and control) varied 424 greatly (>20%) between day 21 and 28. This was notably the case for Clonotype 3 from Donor 1 in the DDB 425 condition, which declined markedly from day 21 to day 28, whereas this clonotype's abundance did not 426 change significantly between day 21 to 28 of DDB exposure in Donor 2 (Figure 6B). We wondered if the 427 clonotypes with altered abundance between day 21 and day 28 in the same donor and condition displayed 428 a specific transcriptional profile. In general, weak changes in transcriptional signatures were detected when 429 comparing a given clonotype and experimental condition between day 28 and day 21. In the DDB condition, 430 clonotype 3 of Donor 1, which showed a decreased abundance from day 21 to day 28, had a higher 431 expression of genes related to T-cell activation, differentiation and exhaustion. This effect seems to be 432 clonotype and donor specific but not condition specific since a similar behavior is seen in the control 433 condition in clonotype 2 of Donor 3 (Figure 6D). Taken together these data show that DDB has limited 434 impact on the clonal diversity of the expanded T cells overtime. The proportion of isolated clones can 435 nonetheless fluctuate in line with their gene expression signatures at day 28. We noticed a weak trend of 436 increased expression of genes related to exhaustion in clonotypes with decreased abundance at day 28 437 and a rise in the expression of genes related to proliferation in clonotypes with an increased abundance at 438 day 28, irrespective of experimental conditions. Globally, these results suggest that DDB confers no 439 consistent transcriptional features to expanded antigen-specific CD8⁺ antigen-specific T cells but may alter 440 activation/dysfunction, cell cycle and metabolic processes in a clonotypes and donor-dependent fashion.

441

442 The benefits of dual PD-L1 and TIM-3 blockade extend to TAA-specific T cells

The EBV-derived LMP2₄₂₆₋₄₃₄ antigen stimulates a memory T-cell repertoire in more than 90% of adults²³. The *ex vivo* expansion of naïve T cells is generally considered more challenging for several reasons (size of the repertoire, amount of stimulation required, etc.). We, therefore, sought to determine the impact of dual PD-L1/TIM-3 blockade in the priming and expansion of naïve T cells. It was previously shown that CD8+ T cells specific against Wilm's tumor 1 (WT1) derived peptides, a clinically relevant tumor-associated antigen (TAA), are phenotypically naïve in healthy individuals²⁴ but can be expanded from a majority of

449 such donors^{25 26}. Volunteer donor T cells were stimulated with an HLA-0201 restricted WT1 peptide (WT1₃₇-450 45) using the same stimulation/expansion conditions for LMP2426-434 specific T cells. Figure 7A-C shows that 451 WT1-specific T cells expanded following a similar pattern as LMP2426-434-specific T cells. The expansion, percentages and number of antigen-specific cells as well as their cytokine secretion were improved in the 452 453 DDB condition relative to cultures without immune checkpoint blockade, again without altering T-cell 454 differentiation patterns or exhaustion marker expression (Figure 6D-G). We conclude that our results 455 obtained with LMP2426-434 extend beyond virus-specific memory T-cell expansion and that double PD-456 L1/TIM-3 immune checkpoint blockade can improve the expansion of functional TAA-specific CD8⁺ T cells 457 from naïve repertoires.

459 Discussion

460 The stimulation and expansion of antigen-specific T cells for adoptive immunotherapy is an attractive 461 strategy to target a wide variety of cancer antigens. However, T-cell expansion is limited by the expression 462 of inhibitory receptors and the development of T-cell dysfunction. We confirmed and extended previous 463 studies revealing that immune checkpoint receptors are expressed on repeatedly activated T cells and that 464 their corresponding ligands can be present on antigen-presenting cells used ex vivo. Co-expression of PD-465 1 and TIM-3 has been used to describe highly exhausted CD8⁺ T cells, and combined blockade of these receptors in murine models has previously been shown to improve tumor control relative to single 466 467 blockade^{18 19 27}. We show that antibody-mediated immune checkpoint blockade targeting PD-1 or TIM-3 468 alone is insufficient to improve CD8⁺T-cell expansion while the combination improves T-cell expansion and 469 antigen-specific reactivity. These data confirm the synergistic potential of immune checkpoint blockade and the particular relevance of TIM-3 and PD-1 as inhibitory receptors in CD8⁺ T cells¹⁹. The reasons for this 470 471 synergistic effect might be due to the mobilization of different signaling intermediates by the two receptors. 472 While PD-1 relies on the recruitment of SHP phosphatases to mediate its effects (as for several other 473 negative co-stimulatory molecules), TIM-3 uses Bat3 and Fyn for its stimulatory and inhibitory effects, 474 respectively. We reasoned that delaying TIM-3 blockade by one week after the start of the culture even in 475 the presence of TIM-3 ligands on APC would be beneficial, given previous experimental evidence that TIM-3 provides activation signals following a first T-cell stimulation^{28 29}. This contrasts with PD-1, which conveys 476 inhibitory signals in both exhausted T cells and early after activation³⁰, justifying the use of anti-PD-L1 at 477 culture initiation. We realize that several refinements may be required to fully leverage the potential 478 479 agonistic/antagonistic effects of TIM-3 on T-cell activation and expansion and determine whether anti PD-480 L1/PD-1 blockade may also be improved by altering the timing of the inhibition. In addition, whether dual 481 PD-L1/TIM-3 blockade improves T-cell expansion and function across multiple types of T-cell 482 manufacturing protocols should be tested, just like further combinations with blockade of additional 483 inhibitory receptors. Nonetheless, our work provides a new strategy for T-cell expansion and offers novel biological insights on the effects of PD-L1/PD-1 axis and TIM-3 blockade in human antigen-specific T-cell 484 485 clonotypes submitted to multiple antigenic stimulations.

486

487 Our data support that sustained dual PD-L1/TIM-3 blockade through several rounds of antigenic 488 stimulations provides ongoing benefits without exacerbating T-cell dysfunction or curbing expansion as inferred by previous studies of using inhibitory receptor gene deletion³¹. This was assessed through 489 490 phenotyping, functional assays, and gene expression in single cells. Our results indicate that antigen-491 specific CD8⁺ T cells expanded under combined TIM-3/PD-L1 blockade are functional as well as specific 492 and that their clonal composition is generally stable in time and relative to their counterpart not exposed to 493 immune checkpoint blockade. It has been reported that immune checkpoint blockade in vivo can shape the 494 T-cell repertoire³²⁻³⁴. Thus, from a perspective of T-cell therapy, it was essential to define whether an 495 intervention during ex vivo T-cell expansion alters the clonal identity of the cellular product. While we did 496 not observe consistent effects of PD-L1/TIM-3 blockade on T-cell transcriptome or clonotype distribution, 497 altered transcriptional profiles in a clonotype and donor-dependent manner nonetheless suggests that 498 immune checkpoint blockade in adoptive T-cell therapy may require personalization.

499

500 Further work will be required to understand why some clonotypes may be more susceptible to 501 differentiation/exhaustion following immune checkpoint blockade (previous activation/proliferation history, 502 differentiation status at the beginning of checkpoint blockade, etc). Nevertheless, our data suggest that 503 even after 28 days in culture, the antigen-specific T cells are highly functional, with a third expressing Tcm 504 markers. This indicates that antigen-specific T cells generated in high numbers after dual immune 505 checkpoint blockade could further expand after transfer and likely respond to further immune checkpoint 506 blockade administered *in vivo*.

507

508 We conclude that dual PD-L1/TIM-3 blockade is a readily applicable strategy to improve the expansion of 509 functional antigen-specific CD8⁺ T cells expansion *ex vivo* for adoptive immunotherapy.

511 **References**

- Janelle V, Rulleau C, Del Testa S, et al. T-Cell Immunotherapies Targeting Histocompatibility and Tumor
 Antigens in Hematological Malignancies. *Front Immunol* 2020;11:276. doi:
 10.3389/fimmu.2020.00276
- 515 2. Chrusciel E, Urban-Wojciuk Z, Arcimowicz L, et al. Adoptive Cell Therapy-Harnessing Antigen-Specific 516 T Cells to Target Solid Tumours. *Cancers (Basel)* 2020;12(3) doi: 10.3390/cancers12030683
- Soppermans N, Kueberuwa G, Hawkins RE, et al. Transgenic T-cell receptor immunotherapy for cancer:
 building on clinical success. *Ther Adv Vaccines Immunother* 2020;8:2515135520933509. doi:
 10.1177/2515135520933509
- 4. Janelle V, Carli C, Taillefer J, et al. Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture. *Journal of translational medicine* 2015;13:123. doi: 10.1186/s12967-015-0495-z
- 523 5. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. *Nat* 524 *Rev Cancer* 2012;12(10):671-84. doi: nrc3322 [pii]
- 525 10.1038/nrc3322 [published Online First: 2012/09/22]
- 526 6. Janelle V, Delisle JS. T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts
 527 and Mitigation Strategies. *Cancers (Basel)* 2021;13(4) doi: 10.3390/cancers13040598
- 528 7. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
 529 *Cancer Discov* 2018;8(9):1069-86. doi: 10.1158/2159-8290.CD-18-0367
- S30 8. Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer
 immunotherapy. *Int J Clin Oncol* 2020 doi: 10.1007/s10147-019-01588-7
- 9. Vaddepally RK, Kharel P, Pandey R, et al. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. *Cancers (Basel)* 2020;12(3) doi: 10.3390/cancers12030738 [published Online First: 2020/04/05]
- 535 10. Schnell A, Bod L, Madi A, et al. The yin and yang of co-inhibitory receptors: toward anti-tumor immunity
 536 without autoimmunity. *Cell Res* 2020;30(4):285-99. doi: 10.1038/s41422-020-0277-x
- 11. Hobo W, Maas F, Adisty N, et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments
 expansion and function of minor histocompatibility antigen-specific CD8+ T cells. *Blood* 2010;116(22):4501-11. doi: 10.1182/blood-2010-04-278739
- 540 12. Boudreau G, Carli C, Lamarche C, et al. Leukoreduction system chambers are a reliable cellular source
 541 for the manufacturing of T-cell therapeutics. *Transfusion* 2019;59(4):1300-11. doi:
 542 10.1111/trf.15121
- 543 13. Orio J, Carli C, Janelle V, et al. Early exposure to interleukin-21 limits rapidly generated anti-Epstein 544 Barr virus T-cell line differentiation. *Cytotherapy* 2015;17(4):496-508. doi:
 545 10.1016/j.jcyt.2014.12.009
- 546 14. Dahmani A, Janelle V, Carli C, et al. TGFbeta Programs Central Memory Differentiation in Ex Vivo 547 Stimulated Human T Cells. *Cancer Immunol Res* 2019;7(9):1426-39. doi: 10.1158/2326-6066.CIR 548 18-0691
- 549 15. Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. *Genome* 550 *Biol* 2018;19(1):15. doi: 10.1186/s13059-017-1382-0
- 16. Levine JH, Simonds EF, Bendall SC, et al. Data-Driven Phenotypic Dissection of AML Reveals
 Progenitor-like Cells that Correlate with Prognosis. Cell 2015;162(1):184-97. doi:
 10.1016/j.cell.2015.05.047
- 17. Nazarov VI, Pogorelyy MV, Komech EA, et al. tcR: an R package for T cell receptor repertoire advanced
 data analysis. *BMC Bioinformatics* 2015;16:175. doi: 10.1186/s12859-015-0613-1
- 18. Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell
 exhaustion phenotype in mice with disseminated acute myelogenous leukemia. *Blood* 2011;117(17):4501-10. doi: 10.1182/blood-2010-10-310425
- 19. Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell
 exhaustion and restore anti-tumor immunity. J Exp Med 2010;207(10):2187-94. doi:
 10.1084/jem.20100643 [published Online First: 2010/09/08]
- 20. Tan J, Yu Z, Huang J, et al. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence
 the clinical outcome of patients with AML. *Biomark Res* 2020;8:6. doi: 10.1186/s40364-020-01858

- 565 21. Gorman JV, Starbeck-Miller G, Pham NL, et al. Tim-3 directly enhances CD8 T cell responses to acute
 566 Listeria monocytogenes infection. J Immunol 2014;192(7):3133-42. doi:
 567 10.4049/jimmunol.1302290
- 22. Azizi E, Carr AJ, Plitas G, et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor
 Microenvironment. *Cell* 2018;174(5):1293-308 e36. doi: 10.1016/j.cell.2018.05.060
- 570 23. Taylor GS, Long HM, Brooks JM, et al. The immunology of Epstein-Barr virus-induced disease. Annu
 571 *Rev Immunol* 2015;33:787-821. doi: 10.1146/annurev-immunol-032414-112326
- Schmied S, Gostick E, Price DA, et al. Analysis of the functional WT1-specific T-cell repertoire in healthy
 donors reveals a discrepancy between CD4(+) and CD8(+) memory formation. *Immunology* 2015;145(4):558-69. doi: 10.1111/imm.12472
- 575 25. Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred WT1-Reactive CD8+ T Cells Can Mediate
 576 Antileukemic Activity and Persist in Post-Transplant Patients. *Sci Transl Med* 2013;5(174):174ra27.
 577 doi: 5/174/174ra27 [pii]
- 578 10.1126/scitranslmed.3004916 [published Online First: 2013/03/01]
- 579 26. Doubrovina E, Carpenter T, Pankov D, et al. Mapping of novel peptides of WT-1 and presenting HLA
 580 alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+)
 581 leukemias. *Blood* 2012;120(8):1633-46. doi: blood-2011-11-394619 [pii]
- 582 10.1182/blood-2011-11-394619 [published Online First: 2012/05/25]
- 583 27. Sun F, Guo ZS, Gregory AD, et al. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic
 584 virotherapy in refractory lung cancer. *J Immunother Cancer* 2020;8(1) doi: 10.1136/jitc-2019 585 000294
- 28. Lee J, Su EW, Zhu C, et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. *Mol Cell Biol* 2011;31(19):3963-74. doi: 10.1128/MCB.05297-11
- 588 29. Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. *Immunol Rev* 2017;276(1):97-111. doi: 10.1111/imr.12520
- 30. Ahn E, Araki K, Hashimoto M, et al. Role of PD-1 during effector CD8 T cell differentiation. *Proc Natl Acad Sci U S A* 2018;115(18):4749-54. doi: 10.1073/pnas.1718217115
- 31. Odorizzi PM, Pauken KE, Paley MA, et al. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med 2015;212(7):1125-37. doi: 10.1084/jem.20142237
- 595 32. Friese C, Harbst K, Borch TH, et al. CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+)
 596 tumor-infiltrating lymphocytes in ovarian cancer. Sci Rep 2020;10(1):3914. doi: 10.1038/s41598 597 020-60738-4
- 33. Rudqvist NP, Pilones KA, Lhuillier C, et al. Radiotherapy and CTLA-4 Blockade Shape the TCR
 Repertoire of Tumor-Infiltrating T Cells. *Cancer Immunol Res* 2018;6(2):139-50. doi: 10.1158/2326 6066.CIR-17-0134
- 34. Han J, Duan J, Bai H, et al. TCR Repertoire Diversity of Peripheral PD-1(+)CD8(+) T Cells Predicts
 Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. Cancer
 Immunol Res 2020;8(1):146-54. doi: 10.1158/2326-6066.CIR-19-0398

605 Figures

Figure 1



607 Figure 1. Repeated antigenic encounters ex vivo leads to antigen-specific T-cell exhaustion. (A) 608 Representative fluorescent multimer staining of LMP2426-434-specific CD8+ T cells (LMP2) and total cellular 609 expansion (expressed as fold change relative to culture input $-15x10^6$ cells). (B) Percentages, as well as 610 (C) calculated number of antigen-specific T cells at the indicated time points (n=10 different donors). (D) Representative staining to determine naïve (Tn), central memory (Tcm), effector memory (Tem), and 611 612 effector T cells (Teff) and the percentage of HLA-A02/LMP2426-434 multimer positive CD8⁺ T cells within 613 these categories at different culture time points (n= 12 different donors). (E) Representative histograms of 614 immune checkpoint expression evaluated relative to fluorescence minus one (FMO) control in HLA-A0201-615 LMP2₄₂₆₋₄₃₄ (LMP2) multimer-stained T cells and compiled results from 12 different donors. (F)

616 Representative staining of PD-1 and TIM-3 co-expression and compiled results from 9-13 different donors.

(H) Percentage expression of PD-1 and TIM-3 ligands on dendritic cells used to stimulate T cells (n=5
different donors). Significant p values are indicated on figure panels. All error bars represent standard
deviation to the mean (SEM).



622 Figure 2. Dual but not single PD-L1 and TIM-3 blockade improves T-cell expansion. (A) Total cell 623 expansion relative to input at the beginning of the culture in function of time and culture condition; no 624 blocking antibodies (ctrl), anti-PD-L1 (α-PD-L1), anti-TIM3 (α-TIM3) or both (double blockade - DB). 625 Absolute count (B) and percentage (C) of HLA-A0201-LMP2426-434 (LMP2) multimer positive T cells in the 626 same conditions and at the same time-points. (D) T-cell differentiation phenotypes; naïve (Tn), central 627 memory (Tcm), effector memory (Tem) and effector T cells (Teff) and (E) percentages of LMP2 multimer 628 positive T cells expressing immune checkpoints in the function of culture conditions and time-points (n=4-629 10 different donors). Significant (<0.05) p-values are indicated on the figure panels. All error bars represent 630 SEM.

631

621



633

Figure 3. Delayed double blockade (DDB) further improves T-cell yield. (A) Total T-cell expansion 634 635 relative to input at day 0 in the function of time and culture condition; no blocking antibodies (Ctrl), double 636 anti-PD-L1 and anti-TIM-3 applied at culture initiation (double blockade - DB), anti-PD-L1 introduced at day 637 0 and anti-TIM-3 introduced at day 7 (delayed double blockade - DDB). (B) Percentages and (C) absolute 638 counts of HLA-A0201-LMP2426-434 (LMP2) multimer positive T cells from the same cultures. (D) T-cell 639 differentiation phenotypes and (E) immune checkpoint expression of LMP2 multimer positive cells in the 640 same culture conditions and time-points (n=8 different donors). Significant (<0.05) p-values are indicated 641 on the figure panels. All error bars represent SEM.



643

Figure 4. DDB expands a high proportion and number of functional antigen-specific T cells. (A) Representative dot plots showing intracellular cytokine secretion following LMP2₄₂₆₋₄₃₄ antigenic restimulation at day 28 and compiled results from 6 independent donor cultures; expansion with no blocking antibodies (CTRL), anti-PD-L1 and anti-TIM3 antibodies both introduced at the beginning of the culture

648 (DB) or both antibodies but anti-TIM3 introduced at day 7 (DDB). (B) IFN-y ELISpot results using 50,000 649 cells per condition harvested from the cultures at the indicated time-points and using the following 650 stimulating conditions: vehicle only (DMSO), anti-CD3 (CD3, positive control), irrelevant peptide (Irr.), 651 LMP2₄₂₆₋₄₃₄ peptide (LMP2). (C) Percentage of Ki-67 staining at day 28 among CD8⁺ T cells from the ctrl 652 vs DDB cultures (n=5 different donors) and (D) co-expression of surface CD107a and intracellular 653 granzyme-b (GzB) as surrogate for degranulation following LMP2426-434 exposure. (E) Fluorescence-based 654 cytotoxicity assay (cell tracer yellow - CTY or cell tracer violet - CTV) showing loss of targets loaded 655 (LMP2+) or not (LMP2-) with the LMP2426-434 antigen (numbers indicate percentages of total events) and 656 (F) compiled results at different target: T-cell ratio (from 3 different donors). The significant p-values are 657 indicated on the panels and error bars indicate SEM.

Figure 5



659

660 Figure 5. Single-cell RNA-sequencing of antigen-specific T cells after double immune checkpoint 661 inhibition.

(A) T-stochastic neighbor embedding (t-SNE) of normalized single-cell gene expression after dimensionality reduction from control (CTRL) and delayed double blockade (DDB) conditions, color coded by donor and experimental condition (CTRL, DDB). (B) Dot plot representing the change in the expression of genes related to pathways of interest in the DDB condition compared to the CTRL condition. The color of the dots represents the log2 fold-change of the genes in the pathway and the size of the dot is representative of the

- 667 percentile ranking of the comparison in random gene sets (see Methods). (C) Clonotype frequencies in the
- 668 CTRL and DDB conditions for each donor. (D) Similar to (B) comparing the cells of selected
- 669 clonotypes/patients between the two experimental conditions. The donor of origin is color coded.

670

Figure 6



672

673 Figure 6. Impact of DDB on clonal diversity and stability in time.

674 (A) Estimate of TCR repertoire diversity using the Gini-Simpson index among HLA-multimer negative and

positive T cells at day 21 and 28. (B) Clonal hierarchy and clonal relatedness among

676 HLA-A0201-LMP2₄₂₆₋₄₃₄ multimer positive T cells between day 21 and 28 based on the day 28 repertoire in

677 the DDB (B) or control condition (C) based on bulk CDR3 sequencing. The control condition in Donor 3 was

not assessed due poor RNA quality at day 28. (D) Dot plot representing the change in the expression of

679 genes related to pathways of interest when comparing a clonotype of interest in a donor/experimental

680 condition to all the other clonotypes in the same donor/condition. The clonotypes selected are those whose

abundance vary by more than 20% between day 21 and 28.



Figure 7. Improved expansion of functional WT1-specific T cells with DDB. (A) Representative HLA-A0201-WT1₃₇₋₄₅ multimer staining (WT1) of CD8⁺ T cells. (B) Cell expansion expressed as fold increase relative to cell input at the beginning of the culture (15x10⁶) in ctrl (no blocking antibodies) or delayed double anti-PD-L1 and anti-TIM3 blockade (DDB) condition, as well as percentage (C) and absolute numbers (D) of WT1-specific T cells at different time-points in culture. (E) Proportion of intracellular cytokine expression following WT1 exposure at day 28 of the culture in CD8⁺ cells and (F) IFN-γ ELISpot results at days 14, 21, and 28 of culture following exposure to vehicle alone (DMSO), a peptide not used in the culture (irrelevant,

- 691 Irr) as negative controls, anti-CD3c (positive control) and the targeted peptide (WT1). (G) T-cell
- differentiation; naïve (Tn), central memory (Tcm), effector memory (Tem), and effector T cells (Teff) and
- (H) percentage of immune checkpoint surface expression on WT-1 specific T cells. Four (4) different
- donors, p-values are indicated on the figures, error bars indicate SEM.